Yesterday it was announced that the European Medicines Agency will relocate from London to Amsterdam. The EMA is an agency of the European Union and its role involves the scientific evaluation, supervision and safety monitoring of medicines for human and animal use as well as assisting national agencies authorise medicine sales within the EU single market.
The EMA has to relocate due to the UK decision to leave the EU and the UK Government’s desire to no longer be subject to the jurisdiction of the European Court of Justice.
EMA has been based in London, UK, since it’s location was secured by John Major’s government in 1995, the year the Agency was established. It currently employs nearly 900 people with a further 36,000 scientists and regulators visiting each year.
A House of Commons Library Research Paper entitled Brexit and medicines regulationlooks at how medicines are currently regulated in the UK, the role of the EMA and what the options are post Brexit.
The European Commission has published documents and position papers on a wide variety of topics since the start of the Article 50 negotiations with the United Kingdom as part of their approach to transparency.
Malta will hold the rotating EU Council presidency from January to July 2017. This is the first time Malta has held the presidency. More information on what the role involves is available here. The six priorities identified by the Maltese government for its presidency are:
A briefing note from the European Parliament Think Tanks looks at these priorities and at other ongoing issues the European Parliament will need to address during this time.
You can follow the Maltese presidency on Facebook.